Developing Vaccines to Improve Preparedness for Filovirus Outbreaks: The Perspective of the USA Biomedical Advanced Research and Development Authority (BARDA)

• Published in: Vaccines (Basel) Vol. 11; no. 6; p. 1120
• Main Authors: Parish, Lindsay A, Stavale, Eric J, Houchens, Christopher R, Wolfe, Daniel N
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.06.2023; MDPI
• Subjects: Adenoviruses; BARDA; Clinical trials; Collaboration; Contact tracing; Ebola; Ebola virus; Epidemics; Fatalities; filovirus; Glycoproteins; Hemorrhage; Hemorrhagic fever; Infections; Infectious diseases; Manufacturing; Marburg; Outbreaks; Prevention; Public health; R&D; Research & development; Review; RNA viruses; vaccine; Vaccines; Viral diseases; Viral infections; Viruses; United States; Uganda; United States > US; West Africa; Sudan; BARDA; vaccine; Marburg; Ebola; filovirus
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines11061120

Outbreaks of viral hemorrhagic fever caused by filoviruses have become more prevalent in recent years, with outbreaks of Ebola virus (EBOV), Sudan virus (SUDV), and Marburg virus (MARV) all occurring in 2022 and 2023. While licensed vaccines are now available for EBOV, vaccine candidates for SUDV and MARV are all in preclinical or early clinical development phases. During the recent outbreak of SUDV virus disease, the Biomedical Advanced Research and Development Authority (BARDA), as part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, implemented key actions with our existing partners to advance preparedness and enable rapid response to the outbreak, while also aligning with global partners involved in the implementation of clinical trials in an outbreak setting. Beyond pre-existing plans prior to the outbreak, BARDA worked with product sponsors to expedite manufacturing of vaccine doses that could be utilized in clinical trials. While the SUDV outbreak has since ended, a new outbreak of MARV disease has emerged. It remains critical that we continue to advance a portfolio of vaccines against SUDV and MARV while also expediting manufacturing activities ahead of, or in parallel if needed, outbreaks.